Clinical trials: Hidradenitis Suppurativa (HS), open to volunteers
Hidradenitis Suppurativa (HS)
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe…
- Trial name
- NCT07489573
- Testing
- Secukinumab
- Where
- 10 sites in China
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
The Safety and Efficacy of Roflumilast Foam in HS
This study investigates the efficacy of topical roflumilast foam in patients with HS.
- Trial name
- NCT07263230
- Testing
- Roflumilast 0.3% topical foam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hidradenitis Suppurativa
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on…
- Trial name
- ANIMA - Italy (NCT07543419)
- Where
- 16 sites in Italy
- Volunteers
- 250 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS), Fecal Microbiota Transplantation (FMT)
FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study
The medical and surgical treatment of hidradenitis suppurativa (HS) remains difficult to date. The search for new therapies for HS is a major challenge.
- Trial name
- FESTIVAL (NCT07668713)
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- 7 sites in France
- Volunteers
- 24 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hidradenitis Suppurativa (HS)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
This study is a Phase Ic/II clinical trial conducted in Chinese patients with moderate-to-severe hidradenitis suppurativa (HS), aiming to evaluate the safety and efficacy of LT-002-158 tablets in the treatment of…
- Trial name
- NCT06932003
- Testing
- LT-002-158 Tablets
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Hidradenitis Suppurativa (HS)
Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment…
- Trial name
- ILLUMINATE-SA (NCT06785779)
- Testing
- Secukinmab
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
- Trial name
- NCT07783542
- Testing
- ORKA-002
- Where
- 25 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Oruka Therapeutics, Inc.
Hidradenitis Suppurativa (HS)
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
Hidradenitis suppurativa (HS) is a long-lasting skin condition that causes painful lumps, abscesses, and tunnels in areas such as the armpits and groin.
- Trial name
- WMCREI (NCT07155239)
- Testing
- AviClear Lase Treatment
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Wynn Medical Center
Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa)
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in…
- Conditions
- Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
- Trial name
- NCT06926192
- Testing
- Surgery combined with secukinumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College
Hidradenitis Suppurativa (HS)
MAIT Cells in Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a chronic, debilitating inflammatory skin disease characterized by painful, purulent lesions primarily in skin folds. Its pathogenesis remains poorly understood.
- Trial name
- HS-MAIT (NCT07388446)
- Testing
- Collect lesional biopsies, Collect score from Bristol stool scale
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Hospices Civils de Lyon
Hidradenitis Suppurativa (HS)
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
Safety and Efficacy of Soquelitinib in Adults with Hidradenitis Suppurativa
- Trial name
- NCT07828860
- Testing
- Soquelitinib
- Where
- 11 sites in United States
- Volunteers
- 25 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Hidradenitis Suppurativa (HS)
A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa
The goal of this clinical trial is to learn if combining an IL-17A/F monoclonal antibody with non-ablative fractional laser therapy works and is safe in patients with mild to moderate hidradenitis suppurativa (HS).
- Trial name
- NCT07554014
- Testing
- IL-17A/F mAb + NAFL
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hidradenitis Suppurativa (HS)
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS.
- Trial name
- Mainsail (NCT07384975)
- Testing
- NAV-240
- Where
- 41 sites in United States, Bulgaria and 6 more
- Volunteers
- 150 people
- Sponsor
- Navigator Medicines, Inc.
Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa)
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
Secukinumab is currently approved in Europe, US and China for the treatment of moderate to severe HS as a biologic agent targeting IL-17A.Two phase III clinical trials (SUNSHINE and SUNRISE) showed that 300 mg s.c.
- Conditions
- Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
- Trial name
- NCT07261072
- Testing
- Topical injection of Secukinmab, Subcutaneous injection of Secukinumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College
Hidradenitis Suppurativa
A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients
The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple…
- Trial name
- EARLY-HS 2 (NCT07690319)
- Volunteers
- 186 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa, Atopic Dermatitis
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort.
- Trial name
- NCT06524635
- Testing
- Lutikizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa (HS)
Exploration of Brain Functional Networks in Patients With Hidradenitis Suppurativa Using fMRI
The goal of this observational study is to learn whether adults with hidradenitis suppurativa (HS) have changes in resting brain activity and how these changes are related to disease severity, pain, sleep, mood, and quality of…
- Trial name
- NCT07755670
- Testing
- Routine Biologic Therapy for Hidradenitis Suppurativa
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Second Xiangya Hospital of Central South University
Hidradenitis Suppurativa
A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
This study aims to better understand how Bruton's tyrosine kinase (BTK) inhibition with remibrutinib works in hidradenitis suppurativa (HS), a complex inflammatory disease with different types of lesions.
- Trial name
- NCT07855276
- Testing
- LOU064
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
Early Pathophysiology of Hidradenitis Suppurativa and Prediction of the Risk of Progression: a Prospective Cohort
Hidradenitis suppurativa (HS) is a chronic inflammatory disease affecting approximately 1% of the population. Most pathophysiological studies have focused on advanced forms (Hurley II-III), which obscures the initial mechanisms.
- Trial name
- Early-HS (NCT07920848)
- Testing
- Biological samples and questionnaires, Analysis of residual skin tissue
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hidradenitis Suppurativa (HS)
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
- Trial name
- STOP-LTR (NCT06855498)
- Testing
- povorcitinib
- Where
- 306 sites in United States, Argentina and 18 more
- Volunteers
- 600 people
- Sponsor
- Incyte Corporation